EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused by Pseudomonas aeruginosa and Staphylococcus aureus

Céline Boidin-Wichlacz iD, Marc Maresca iD, Teddy Grandjean, Axelle Grandé, Orane Huchez iD, Katy Jeannot iD, Rémi Desmet, Benoît Snella, Nicolas Vidal, Laure Genet, Stéphanie Caby iD, Magalie Sénéchal und 5 weitere

Marine Drugs · 05.05.2026 · 24 (5) · 164

DOI: 10.3390/md24050164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 05.05.2026. Verfasst von Céline Boidin-Wichlacz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, Franc…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Staphylococcus aureus, Cystic Fibrosis, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: intraCIIL, ULille, AMU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF)-associated lung infections caused by Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus) remain difficult to treat due to multidrug resistance and the redox instability of the pulmonary environment, which can impair antibiotic efficacy. In this study, we investigated alvinellacin (ALV), a disulfide-stabilized β-hairpin antimicrobial peptide (AMP) derived from the deep-sea polychaete Alvinella pompejana (A. pompejana), as a potential therapeutic agent naturally adapted to redox-fluctuating conditions. The antibacterial and antibiofilm activities of ALV were evaluated against multidrug-resistant (MDR) clinical isolates under CF-like reducing conditions (6 mM dithiothreitol (DTT)). Circular dichroism (CD) analysis showed that DTT did not alter the β-hairpin secondary structure of ALV, supporting its structural stability in CF-like environments. Mechanistic analyses included pore-forming assay, membrane interaction studies, scanning electron microscopy (SEM), lipid-binding assays, cytotoxicity testing, and resistance induction assays, while in vivo efficacy was assessed using the Galleria mellonella infection model. ALV demonstrated strong bactericidal activity that was maintained in the presence of NaCl or human serum. ALV did not induce bacterial resistance and effectively inhibited early-stage biofilm formation and disrupted preformed biofilms, including those of the clinical isolate, even under reducing conditions. The peptide showed selective permeabilization of bacterial membranes linked to its stronger affinity for bacterial membrane lipids and negligible interaction with host-like membranes, with no observed cytotoxicity. In vivo, ALV significantly improved survival in infected larvae. These findings highlight ALV as a promising redox-resilient antimicrobial candidate for treating MDR CF lung infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaStaphylococcus aureusCystic FibrosisAnti-Bacterial AgentsAntimicrobial PeptidesStaphylococcal InfectionsPolychaetaPseudomonas InfectionsAnimalsBiofilmsHumansMicrobial Sensitivity TestsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

antibiofilmantibioticbiomimicryextremophilelungredoxresistanceworms

Substanzen

Anti-Bacterial AgentsAntimicrobial Peptides

Autor:innen und Institutionen

  • Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.
  • Aix Marseille Univ, CNRS, Centrale Med, ISM2, F-13013 Marseille, France.
  • Université Marie et Louis Pasteur, CHU Besançon, CNRS, Chrono-Environnement (UMR 6249), F-25000 Besançon, France.
  • Yelen Analytics, 10 bd tempête, F-13820 Ensues La Redonne, France.
  • Institut de Recherche Biomédicale des Armées (IRBA)-UMR-MD1-Inserm 1261, F-91220 Brétigny-Sur-Orge, France.
  • Aix Marseille Univ, INSERM, SSA, MCT, F-13385 Marseille, France.

ORCID-Profile: Céline Boidin-Wichlacz, Marc Maresca, Orane Huchez, Katy Jeannot, Stéphanie Caby, Sophie Guillier, Oleg Melnyk, Aurélie Tasiemski

Förderung

  • intraCIIL
  • ULille
  • AMU

Zitieren

APA

Boidin-Wichlacz, C., Maresca, M., Grandjean, T., Grandé, A., Huchez, O., Jeannot, K., Desmet, R., Snella, B., Vidal, N., Genet, L., Caby, S., Sénéchal, M., Guillier, S., Ripoll-Neulat, F., Melnyk, O., Pichavant, M., & Tasiemski, A. (2026). Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused by Pseudomonas aeruginosa and Staphylococcus aureus. Marine Drugs, 24(5), 164. https://doi.org/10.3390/md24050164

Vancouver

Boidin-Wichlacz C, Maresca M, Grandjean T, Grandé A, Huchez O, Jeannot K, et al. Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused by Pseudomonas aeruginosa and Staphylococcus aureus. Marine Drugs. 2026;24(5):164. doi:10.3390/md24050164

BibTeX
@article{BoidinWichlacz2026,
  author = {Boidin-Wichlacz, Céline and Maresca, Marc and Grandjean, Teddy and Grandé, Axelle and Huchez, Orane and Jeannot, Katy and Desmet, Rémi and Snella, Benoît and Vidal, Nicolas and Genet, Laure and Caby, Stéphanie and Sénéchal, Magalie and Guillier, Sophie and Ripoll-Neulat, Fabienne and Melnyk, Oleg and Pichavant, Muriel and Tasiemski, Aurélie},
  title = {Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused by Pseudomonas aeruginosa and Staphylococcus aureus},
  journal = {Marine Drugs},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {164},
  doi = {10.3390/md24050164}
}
Kostenlos starten →